Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Nat Rev Neurosci. 2001-08-01; 2(8): 577-588
DOI: 10.1038/35086062
Read on PubMed
1. Nat Rev Neurosci. 2001 Aug;2(8):577-88.
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Bezard E(1), Brotchie JM, Gross CE.
Author information:
(1)Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Université Victor
Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France.
Involuntary movements–or dyskinesias–are a debilitating complication of
levodopa therapy for Parkinson’s disease, and is experienced in most patients.
Despite the importance of this problem, little was known about the cause of
dyskinesia until recently; however, this situation has changed significantly in
the past few years. Our increased understanding of levodopa-induced dyskinesia is
not only valuable for improving patient care, but also in providing us with new
insights into the functional organization of the basal ganglia and motor systems.
DOI: 10.1038/35086062
PMID: 11484001 [Indexed for MEDLINE]